ClinicalTrials.Veeva

Menu
The trial is taking place at:
A

Aventiv Research | Aventiv Research Columbus

Veeva-enabled site

Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seronegative Children 6-36 Months

M

Meissa Vaccines

Status and phase

Enrolling
Phase 1

Conditions

Respiratory Syncytial Virus (RSV)

Treatments

Biological: Investigational RSV vaccine MV-012-968 (Dosage 3; single-dose)
Other: Placebo (two-dose)
Other: Placebo (single-dose)
Biological: Investigational RSV vaccine MV-012-968 (Dosage 2)
Biological: Investigational RSV vaccine MV-012-968 (Dosage 3; two-dose)
Biological: Investigational RSV vaccine MV-012-968 (Dosage 1)

Study type

Interventional

Funder types

Industry

Identifiers

Details and patient eligibility

About

This study evaluates an investigational vaccine that is designed to protect humans against infection with respiratory syncytial virus (RSV) and is administered as a nasal spray. Specifically, the study analyzes the safety of, and the immune response to, the vaccine when administered to healthy children between the ages of 6 and 24 months who are seronegative to RSV.

Enrollment

63 estimated patients

Sex

All

Ages

6 to 36 months old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Key Inclusion Criteria:

  1. Children aged 6-36 months
  2. Good health based on history, physical examination, and medical record review, without evidence or suspicion of chronic disease
  3. Seronegative to RSV, as defined by serum nAb titer below the threshold described in the study protocol and operations manual
  4. Written informed consent provided by parent(s)/guardian(s)

Key Exclusion Criteria:

  1. Known or suspected chronic illness, particularly cardiopulmonary (including asthma or reactive airways disease), genetic or metabolic, hepatic, renal, infectious (including recurrent or chronic sinusitis), or immunodeficiency
  2. Prior lab-confirmed RSV infection
  3. Household or close contact (including but not limited to daycare) during the 21 days post-inoculation with anyone < 6 months old or immunocompromised (applies to first study inoculation)
  4. Nasal obstruction (including due to anatomic/structural causes, acute or chronic rhinosinusitis, or other causes)
  5. Receipt of immunoglobulins, monoclonal antibodies and/or any blood products, or ribavirin within 6 months prior to study inoculation, or planned use during study period
  6. Receipt of an investigational RSV vaccine at any time
  7. Any other condition that, in the judgment of the investigator, would be a risk to subject's safety and/or may interfere with study procedures or interpretation of results

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Sequential Assignment

Masking

Single Blind

63 participants in 6 patient groups, including a placebo group

Dosage Group 1: RSV Vaccine Dosage 1
Experimental group
Description:
Participants in this arm will receive a single intranasal dose of the investigational RSV vaccine at Dosage 1
Treatment:
Biological: Investigational RSV vaccine MV-012-968 (Dosage 1)
Dosage Group 2: RSV Vaccine Dosage 2
Experimental group
Description:
Participants in this arm will receive a single intranasal dose of the investigational RSV vaccine at Dosage 2
Treatment:
Biological: Investigational RSV vaccine MV-012-968 (Dosage 2)
Dosage Group 3: RSV Vaccine Dosage 3 (Single-dose)
Experimental group
Description:
Participants in this arm will receive a single intranasal dose of the investigational RSV vaccine at Dosage 3
Treatment:
Biological: Investigational RSV vaccine MV-012-968 (Dosage 3; single-dose)
Dosage Group 3a: RSV Vaccine Dosage 3 (Two-dose)
Experimental group
Description:
Participants in this arm will receive a single intranasal dose of the investigational RSV vaccine at Dosage 3 followed by a second identical dose of the investigational RSV vaccine 28 days later
Treatment:
Biological: Investigational RSV vaccine MV-012-968 (Dosage 3; two-dose)
Placebo (Single-dose)
Placebo Comparator group
Description:
Participants in this arm will receive a single intranasal dose of placebo
Treatment:
Other: Placebo (single-dose)
Placebo (Two-dose)
Placebo Comparator group
Description:
Participants in this arm will receive a single intranasal dose of placebo followed by a second identical dose of placebo 28 days later
Treatment:
Other: Placebo (two-dose)

Trial contacts and locations

12

Loading...

Central trial contact

Jay Lieberman, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems